Cingulate therapeutics headquarters
WebCingulate Therapeutics is headquartered in Mission, 1901 W 47th Pl, United States, and has 2 office locations. WebJul 11, 2024 · 11 Jul 2024 Cingulate CEO: $7.5M fundraising round will help drive pharma growth in KC. A former Marion Laboratories employee, Shane Schaffer’s goal from the …
Cingulate therapeutics headquarters
Did you know?
WebCingulate Therapeutics is a biopharmaceutical company developing products for the treatment of central nervous system and neurobiological disorders. WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ …
WebApr 6, 2024 · Alterity Therapeutics NASDAQ:ATHE; View All Competitors. Insiders & Institutions. HighTower Advisors LLC Bought 34,425 shares on 2/9/2024 Ownership: … WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing.
WebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% from the latest price. WebJun 24, 2024 · Virtual. We are pleased to invite you to a virtual call series highlighting the next generation of life sciences private companies from Monday, June 29 th – Thursday, July 2 nd, 2024. We will be hosting the companies for 35 minute presentations with time for Q&A over the four days.
WebJul 11, 2024 · Jul 11, 2024. Updated Jul 11, 2024, 2:54pm CDT. Cingulate Therapeutics LLC, a Kansas City, Kan., pharmaceutical startup, received a big equity investment and …
dated ufmaWebJun 15, 2024 · Kansas City, KS – (June 15, 2024) – Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that it has moved the location of its Kansas City headquarters. bivalirudin adverse effectsWebCingulate Therapeutics 9 years 11 months Chief Operating Officer Oct 2024 - Present5 years 7 months Kansas City, KS Founding member of … bivalirudin and pciWebJun 15, 2024 · KANSAS CITY, Kan., June 15, 2024 /PRNewswire/ -- Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused … bivalirudin and dialysisWebMr. Peter Werth serves as Board Member at Cingulate Therapeutics. He is the Founder and also serves as Chief Executive Officer at Werth Ventures. He serves as Board Member at Alopexx Enterprises. He is the Owner & serves as the Chief Executive Officer & President at Chemwerth. He also served as a board member at InnoPharma. bival for hitWebCingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical... bivalirudin and heparinWebJun 16, 2024 · Cingulate Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment … dated weekly planner